DISCO App: study protocol for a randomized controlled trial to test the effectiveness of a patient intervention to reduce the financial burden of cancer in a diverse patient population

Lauren M Hamel, David W Dougherty, Seongho Kim, Elisabeth I Heath, Lorna Mabunda, Eyouab Tadesse, RaeAnn Hill, Susan Eggly, Lauren M Hamel, David W Dougherty, Seongho Kim, Elisabeth I Heath, Lorna Mabunda, Eyouab Tadesse, RaeAnn Hill, Susan Eggly

Abstract

Background: Financial toxicity, the material and psychological burden of the cost of treatment, affects 30-50% of people with cancer, even those with health insurance. The burden of treatment cost can affect treatment adherence and, ultimately, mortality. Financial toxicity is a health equity issue, disproportionately affecting patients who are racial/ethnic minorities, have lower incomes, and are < 65 years old. Patient education about treatment cost and patient-oncologist cost discussions are recommended as ways to address financial toxicity; however, research shows cost discussions occur infrequently (Altice et al. J Natl Cancer Inst 109:djw205, 2017; Schnipper et al. J Clin Oncol 34:2925-34, 2016; Zafar et al. Oncologist 18:381-90, 2013; American Cancer Society Cancer Action Network 2010). Our overall goal is to address the burden of financial toxicity and work toward health equity through a tailorable education and communication intervention, the DISCO App. The aim of this longitudinal randomized controlled trial is to test the effectiveness of the DISCO App on the outcomes in a population of economically and racially/ethnically diverse cancer patients from all age groups.

Methods: Patients diagnosed with breast, lung, colorectal, or prostate cancer at a NCI-designated comprehensive cancer center in Detroit, MI, will be randomized to one of three study arms: one usual care arm (arm 1) and two intervention arms (arms 2 and 3). All intervention patients (arms 2 and 3) will receive the DISCO App before the second interaction with their oncologist, and patients in arm 3 will receive an intervention booster. The DISCO App, presented on an iPad, includes an educational video about treatment costs, ways to manage them, and the importance of discussing them with oncologists. Patients enter socio-demographic information (e.g., employment, insurance status) and indicate their financial concerns. They then receive a tailored list of questions to consider asking their oncologist. All patients will have up to two interactions with their oncologist video recorded and complete measures at baseline, after the recorded interactions and at 1, 3, 6, and 12 months after the second interaction. Outcome measures will assess discussions of cost, communication quality, knowledge of treatment costs, self-efficacy for treatment cost management, referrals for support, short- and longer-term financial toxicity, and treatment adherence.

Discussion: If effective, this intervention will improve awareness of and discussions of treatment cost and alleviate the burden of financial toxicity. It may be especially helpful to groups disproportionately affected by financial toxicity, helping to achieve health equity.

Trial registration: ClinicalTrials.gov NCT04766190. Registered on February 23, 2021.

Keywords: App-based intervention; Cancer treatment cost discussion; Financial toxicity; Patient active participation; Question prompt list; Randomized controlled trial.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Conceptual model
Fig. 2
Fig. 2
SPIRIT figure for the study period for patient participants
Fig. 3
Fig. 3
Flow diagram of participant enrollment, randomization, and procedures
Fig. 4
Fig. 4
DISCO App educational video and QPL introduction screens
Fig. 5
Fig. 5
Oncologist tip
Fig. 6
Fig. 6
Graphical representation of Hierarchical Holm’s Testing

References

    1. Altice CK, Banegas MP, Tucker-Seeley RD, et al. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2017;109.
    1. Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34:2925–2934. doi: 10.1200/JCO.2016.68.2518.
    1. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18:381–390. doi: 10.1634/theoncologist.2012-0279.
    1. Network ACSCA. A national poll: facing cancer in the health care system. 2010.
    1. Zafar SY, McNeil RB, Thomas CM, et al. Population-based assessment of cancer survivors’ financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2015;11:145–150. doi: 10.1200/JOP.2014.001542.
    1. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117–128. doi: 10.1093/jnci/djq495.
    1. The Kaiser Family Foundation. 2015 Employer Health Benefits Survey. .
    1. American Society of Clinical Oncology The State of Cancer Care in America, 2016: a report by the American Society of Clinical Oncology. J Oncol Pract. 2016;12:339. doi: 10.1200/JOP.2015.010462.
    1. PricewaterhouseCoopers. Medical cost trend: behind the numbers 2016. .
    1. Collins SR, Rasmussen PW, Doty MM, et al. Americans’ experiences with marketplace and medicaid coverage. Findings from the Commonwealth Fund Affordable Care Act Tracking Survey, March-May 2015. Issue Brief (Commonw Fund) 2015;16:1–17.
    1. Guy GP, Jr, Ekwueme DU, Yabroff KR, et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol. 2013;31:3749–3757. doi: 10.1200/JCO.2013.49.1241.
    1. Ramsey S, Blough D, Kirchhoff A, et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 2013;32:1143–1152. doi: 10.1377/hlthaff.2012.1263.
    1. Bernard DS, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011;29:2821–2826. doi: 10.1200/JCO.2010.33.0522.
    1. Meneses K, Azuero A, Hassey L, et al. Does economic burden influence quality of life in breast cancer survivors? Gynecol Oncol. 2012;124:437–443. doi: 10.1016/j.ygyno.2011.11.038.
    1. Shankaran V, Jolly S, Blough D, et al. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol. 2012;30:1608–1614. doi: 10.1200/JCO.2011.37.9511.
    1. Sasser AC, Rousculp MD, Birnbaum HG, et al. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Womens Health Issues. 2005;15:97–108. doi: 10.1016/j.whi.2004.11.006.
    1. Sharp L, Carsin AE, Timmons A. Associations between cancer-related financial stress and strain and psychological well-being among individuals living with cancer. Psychooncology. 2013;22:745–755. doi: 10.1002/pon.3055.
    1. Chino F, Peppercorn J, Taylor DH, Jr, et al. Self-reported financial burden and satisfaction with care among patients with cancer. Oncologist. 2014;19:414–420. doi: 10.1634/theoncologist.2013-0374.
    1. Delgado-Guay M, Ferrer J, Rieber AG, et al. Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients. Oncologist. 2015;20:1092–1098. doi: 10.1634/theoncologist.2015-0026.
    1. Zullig LL, Peppercorn JM, Schrag D. Financial distress, use of cost-coping strategies, and adherence to prescription medication among patients with cancer. J Oncol Pract. 2013;9:60s–63s. doi: 10.1200/JOP.2013.000971.
    1. Jagsi R, Pottow JA, Griffith KA, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol. 2014;32:1269–1276. doi: 10.1200/JCO.2013.53.0956.
    1. Pisu M, Azuero A, Meneses K, et al. Out of pocket cost comparison between Caucasian and minority breast cancer survivors in the Breast Cancer Education Intervention (BCEI) Breast Cancer Res Treat. 2011;127:521–529. doi: 10.1007/s10549-010-1225-0.
    1. Pisu M, Kenzik KM, Oster RA, et al. Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer? Cancer. 2015;121:1257–1264. doi: 10.1002/cncr.29206.
    1. Bradley CJ, Wilk A. Racial differences in quality of life and employment outcomes in insured women with breast cancer. J Cancer Surviv. 2014;8:49–59. doi: 10.1007/s11764-013-0316-4.
    1. Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34:980–986. doi: 10.1200/JCO.2015.64.6620.
    1. de Boer AG, Taskila T, Ojajarvi A, et al. Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA. 2009;301:753–762. doi: 10.1001/jama.2009.187.
    1. Pisu M, Azuero A, Benz R, et al. Out-of-pocket costs and burden among rural breast cancer survivors. Cancer Med. 2017;6:572–581. doi: 10.1002/cam4.1017.
    1. Neumann PJ, Palmer JA, Nadler E, et al. Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff (Millwood) 2010;29:196–202. doi: 10.1377/hlthaff.2009.0077.
    1. Meropol NJ, Wong YN, Albrecht T, et al. Randomized trial of a web-based intervention to address barriers to clinical trials. J Clin Oncol. 2016;34:469–478. doi: 10.1200/JCO.2015.63.2257.
    1. Wong YN, Schluchter MD, Albrecht TL, et al. Financial concerns about participation in clinical trials among patients with cancer. J Clin Oncol. 2016;34:479–487. doi: 10.1200/JCO.2015.63.2463.
    1. Wong YN, Egleston BL, Sachdeva K, et al. Cancer patients’ trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care. 2013;51:838–845. doi: 10.1097/MLR.0b013e31829faffd.
    1. Markman M, Luce R. Impact of the cost of cancer treatment: an internet-based survey. J Oncol Pract. 2010;6:69–73. doi: 10.1200/JOP.091074.
    1. Weckstein DJ, Thomas CA, Emery IF, et al. Assessment of perceived cost to the patient and other barriers to clinical trial participation. J Oncol Pract. 2011;7:330–333. doi: 10.1200/JOP.2011.000236.
    1. Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32:306–311. doi: 10.1200/JCO.2013.52.9123.
    1. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29:2534–2542. doi: 10.1200/JCO.2010.33.3179.
    1. Kent EE, Forsythe LP, Yabroff KR, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119:3710–3717. doi: 10.1002/cncr.28262.
    1. Lin CC, Bruinooge SS, Kirkwood MK, et al. Association between geographic access to cancer care, insurance, and receipt of chemotherapy: geographic distribution of oncologists and travel distance. J Clin Oncol. 2015;33:3177–3185. doi: 10.1200/JCO.2015.61.1558.
    1. Streeter SB, Schwartzberg L, Husain N, et al. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011;7:46 s–51 s. doi: 10.1200/JOP.2011.000316.
    1. Bath C. Disclosing medical costs can help avoid ‘financial toxicity’. ASCO Post 2013.
    1. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563–2577. doi: 10.1200/JCO.2015.61.6706.
    1. Ubel PA. Doctor, first tell me what it costs. New York: New York Times; 2013. .
    1. Ubel PA, Abernethy AP, Zafar SY. Full disclosure--out-of-pocket costs as side effects. N Engl J Med. 2013;369:1484–1486. doi: 10.1056/NEJMp1306826.
    1. Smith SK, Nicolla J, Zafar SY. Bridging the gap between financial distress and available resources for patients with cancer: a qualitative study. J Oncol Pract. 2014;10:e368–e372. doi: 10.1200/JOP.2013.001342.
    1. Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68:153–165. doi: 10.3322/caac.21443.
    1. Bullock AJ, Hofstatter EW, Yushak ML, et al. Understanding patients’ attitudes toward communication about the cost of cancer care. J Oncol Pract. 2012;8:e50–e58. doi: 10.1200/JOP.2011.000418.
    1. Irwin B, Kimmick G, Altomare I, et al. Patient experience and attitudes toward addressing the cost of breast cancer care. Oncologist. 2014;19:1135–1140. doi: 10.1634/theoncologist.2014-0117.
    1. Jagsi R, Ward KC, Abrahamse PH, et al. Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer. Cancer. 2018;124:3668–3676. doi: 10.1002/cncr.31532.
    1. Hamel LM, Penner LA, Eggly S, et al. Do patients and oncologists discuss the cost of cancer treatment? An observational study of clinical interactions between African American patients and their oncologists. J Oncol Pract. 2017;13:e249–ee58. doi: 10.1200/JOP.2016.015859.
    1. Ubel PA, Zhang CJ, Hesson A, et al. Study of physician and patient communication identifies missed opportunities to help reduce patients’ out-of-pocket spending. Health Aff (Millwood) 2016;35:654–661. doi: 10.1377/hlthaff.2015.1280.
    1. Jagsi R, Sulmasy DP, Moy B. Value of cancer care: ethical considerations for the practicing oncologist. Am Soc Clin Oncol Educ Book. 2014:e146–9.
    1. ASCO Answers. Managing the Cost of Cancer Care. Alexandria: American Society of Clinical Oncology (ASCO); 2015.
    1. Gilligan T, Coyle N, Frankel RM, et al. Patient-clinician communication: American Society of Clinical Oncology Consensus Guideline. J Clin Oncol. 2017;35:3618–3632. doi: 10.1200/JCO.2017.75.2311.
    1. Eggly S, Hamel LM, Foster TS, et al. Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologists. Patient Educ Couns. 2017;100:818–826. doi: 10.1016/j.pec.2016.12.026.
    1. Clayton JM, Butow PN, Tattersall MH, et al. Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care. J Clin Oncol. 2007;25:715–723. doi: 10.1200/JCO.2006.06.7827.
    1. Street RL, Jr, Makoul G, Arora NK, et al. How does communication heal? Pathways linking clinician-patient communication to health outcomes. Patient Educ Couns. 2009;74:295–301. doi: 10.1016/j.pec.2008.11.015.
    1. de Haes H, Bensing J. Endpoints in medical communication research, proposing a framework of functions and outcomes. Patient Educ Couns. 2009;74:287–294. doi: 10.1016/j.pec.2008.12.006.
    1. Cegala DJ, Street RL, Jr, Clinch CR. The impact of patient participation on physicians’ information provision during a primary care medical interview. Health Commun. 2007;21:177–185. doi: 10.1080/10410230701307824.
    1. Cegala DJ, Chisolm DJ, Nwomeh BC. Further examination of the impact of patient participation on physicians’ communication style. Patient Educ Couns. 2012;89:25–30. doi: 10.1016/j.pec.2012.03.022.
    1. Street RL, Jr, Slee C, Kalauokalani DK, et al. Improving physician-patient communication about cancer pain with a tailored education-coaching intervention. Patient Educ Couns. 2010;80:42–47. doi: 10.1016/j.pec.2009.10.009.
    1. Street RL, Jr, Tancredi DJ, Slee C, et al. A pathway linking patient participation in cancer consultations to pain control. Psychooncology. 2014;23:1111–1117. doi: 10.1002/pon.3518.
    1. Keinki C, Momberg A, Clausb K, et al. Effect of question prompt lists for cancer patients on communication and mental health outcomes - a systematic review. Patient Educ Couns 2021;E-pub version available before print.
    1. Rodenbach RA, Brandes K, Fiscella K, et al. Promoting end-of-life discussions in advanced cancer: effects of patient coaching and question prompt lists. J Clin Oncol. 2017;35:842–851. doi: 10.1200/JCO.2016.68.5651.
    1. Hibbard JH. Patient activation and the use of information to support informed health decisions. Patient Educ Couns. 2017;100:5–7. doi: 10.1016/j.pec.2016.07.006.
    1. Greene J, Hibbard JH. Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med. 2012;27:520–526. doi: 10.1007/s11606-011-1931-2.
    1. Dimoska A, Butow PN, Dent E, et al. An examination of the initial cancer consultation of medical and radiation oncologists using the Cancode interaction analysis system. Br J Cancer. 2008;98:1508–1514. doi: 10.1038/sj.bjc.6604348.
    1. Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open. 2013;3.
    1. Bestvina CM, Zullig LL, Rushing C, et al. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014;10:162–167. doi: 10.1200/JOP.2014.001406.
    1. Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47:826–834. doi: 10.1097/MLR.0b013e31819a5acc.
    1. Brandes K, Linn AJ, Butow PN, et al. The characteristics and effectiveness of question prompt list interventions in oncology: a systematic review of the literature. Psychooncology. 2015;24:245–252. doi: 10.1002/pon.3637.
    1. Dimoska A, Tattersall MH, Butow PN, et al. Can a “prompt list” empower cancer patients to ask relevant questions? Cancer. 2008;113:225–237. doi: 10.1002/cncr.23543.
    1. Sansoni JE, Grootemaat P, Duncan C. Question prompt lists in health consultations: a review. Patient Educ Couns. 2015;12:1454–1464. doi: 10.1016/j.pec.2015.05.015.
    1. Henselmans I, de Haes HC, Smets EM. Enhancing patient participation in oncology consultations: a best evidence synthesis of patient-targeted interventions. Psychooncology. 2013;22:961–977. doi: 10.1002/pon.3099.
    1. Hamel LM, Thompson HS, Albrecht TL, et al. Designing and testing apps to support patients with cancer: looking to behavioral science to lead the way. JMIR Cancer. 2019;5:e12317. doi: 10.2196/12317.
    1. Zickuhr K, Smith A. Digital differences. Pew Internet and American Life Project Website.
    1. Anderson M. Technology device ownership: 2015
    1. Fox S, Duggan M. Mobile Health 2012. Pew Internet and American Life Project Website.
    1. Fox S, Duggan M. Health Online 2013. Pew Internet and American Life Project Website.
    1. Lee R. Digital Divides 2016. Pew Research Center.
    1. Thompson HS, Shelton RC, Mitchell J, et al. Inclusion of underserved racial and ethnic groups in cancer intervention research using new media: a systematic literature review. J Natl Cancer Inst Monogr. 2013;2013:216–223. doi: 10.1093/jncimonographs/lgt031.
    1. Sly JR, Miller SJ, Jandorf L. The digital divide and health disparities: a pilot study examining the use of short message service (SMS) for colonoscopy reminders. J Racial and Ethnic Health Disparities. 2014;1:231–237. doi: 10.1007/s40615-014-0029-z.
    1. Krebs P, Prochaska JO, Rossi JS. A meta-analysis of computer-tailored interventions for health behavior change. Prev Med. 2010;51:214–221. doi: 10.1016/j.ypmed.2010.06.004.
    1. Kreuter MW, Wray RJ. Tailored and targeted health communication: strategies for enhancing information relevance. Am J Health Behav. 2003;27(Suppl 3):S227–S232. doi: 10.5993/AJHB.27.1.s3.6.
    1. Zhao J, Freeman B, Li M. Can mobile phone apps influence people’s health behavior change? An evidence review. J Med Internet Res. 2016;18:e287. doi: 10.2196/jmir.5692.
    1. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. doi: 10.3322/caac.21654.
    1. Albrecht TL, Ruckdeschel JC, Ray FL 3rd, et al. A portable, unobtrusive device for videorecording clinical interactions. Behav Res Methods. 2005;37:165–9.
    1. Penner LA, Orom H, Albrecht TL, et al. Camera-related behaviors during video recorded medical interactions. Journal of Nonverbal Behavior 2007;31:99-117.
    1. Hamel LM, Eggly S, Hastert TA, et al. Acceptability of a patient-focused application-based question prompt list for cancer treatment cost. Porto, Portugal: International Conference on Communication and Healthcare; 2018.
    1. Alexander GC, Casalino LP, Tseng CW, et al. Barriers to patient-physician communication about out-of-pocket costs. J Gen Intern Med. 2004;19:856–860. doi: 10.1111/j.1525-1497.2004.30249.x.
    1. Altomare I, Irwin B, Zafar SY, et al. ReCAP: physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2016;12:247–248. doi: 10.1200/JOP.2015.007401.
    1. Street RL, Jr, Gordon H, Haidet P. Physicians’ communication and perceptions of patients: is it how they look, how they talk, or is it just the doctor? Soc Sci Med. 2007;65:586–598. doi: 10.1016/j.socscimed.2007.03.036.
    1. de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 2014;120:3245–3253. doi: 10.1002/cncr.28814.
    1. Peterson AM, Harper FW, Albrecht TL, et al. Parent caregiver self-efficacy and child reactions to pediatric cancer treatment procedures. J Pediatr Oncol Nurs. 2014;31(1):18–27.
    1. Eggly S, Tkatch R, Penner LA, et al. Development of a question prompt list as a communication intervention to reduce racial disparities in cancer treatment. J Cancer Educ. 2013;28:282–289. doi: 10.1007/s13187-013-0456-2.
    1. Albrecht TL, Eggly SS, Gleason ME, et al. Influence of clinical communication on patients’ decision making on participation in clinical trials. J Clin Oncol. 2008;26:2666–2673. doi: 10.1200/JCO.2007.14.8114.
    1. Eggly S, Albrecht TL, Harper FW, et al. Oncologists’ recommendations of clinical trial participation to patients. Patient Educ Couns. 2008;70:143–148. doi: 10.1016/j.pec.2007.09.019.
    1. Eggly S, Harper FW, Penner LA, et al. Variation in question asking during cancer clinical interactions: a potential source of disparities in access to information. Patient Educ Couns. 2011;82:63–68. doi: 10.1016/j.pec.2010.04.008.
    1. Donner A, Donald A. Analysis of data arising from a stratified design with the cluster as unit of randomization. Stat Med. 1987;6:43–52. doi: 10.1002/sim.4780060106.
    1. Hays RD, Kravitz RL, Mazel RM, et al. The impact of patient adherence on health outcomes for patients with chronic disease in the Medical Outcomes Study. J Behav Med. 1994;17(4):347–60.
    1. Donner AK, N. Design and analysis of cluster randomization trials in health research. London: Arnold; 2000.
    1. Hamel L, Dougherty DW, Hastert TA, et al. The DISCO App: a pilot test of an electronic patient intervention to reduce the financial burden of cancer through improved cost communication. American Society of Clincial Oncology Quality Care Symposium; 2020; Virtual Presentation.
    1. Wu S, Crespi CM, Wong WK. Comparison of methods for estimating the intraclass correlation coefficient for binary responses in cancer prevention cluster randomized trials. Contemp Clin Trials. 2012;33(5):869–80.
    1. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:377–399. doi: 10.1002/sim.4067.
    1. Honaker J, King G. What to do about missing values in time-series cross-section data. Am J Polit Sci. 2010;54:561–581. doi: 10.1111/j.1540-5907.2010.00447.x.
    1. Honaker J, King G, Blackwell M. Amelia II: a program for missing data. J Stat Softw. 2011;45:1–47. doi: 10.18637/jss.v045.i07.
    1. Smith A. U.S. Smartphone use in 2015. .
    1. Eggly S, Hamel LM, Heath E, et al. Partnering Around Cancer Clinical Trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials. BMC Cancer. 2017;17:807. doi: 10.1186/s12885-017-3804-5.

Source: PubMed

3
S'abonner